News

Advanced NSCLC: Targeting the CD73/Adenosine Pathway

Role of Bilateral Mediastinal Lymphadenectomy in Stage I NSCLC

Case Report: A Nonsmoking Welder Develops Rare NSCLC

How Useful Is CT Imaging in Identifying Atherosclerosis in Patients With Lung Cancer?

Using Gene-Edited Stem Cells and Oncolytic Viruses to Treat Lung Cancer Brain Metastases

Could Computable Phenotypes Determine Eligibility for Lung Cancer Screening?

Comparing Operative Approaches in the Management of NSCLC

Can ORACLE Predict Survival and Chemotherapy Response in Lung Adenocarcinoma?

NSCLC: Another Cancer in Which CD47 Expression Makes a Difference

Study Finds Potential Clinical Use of EGFR TKIs in BRAF Class 3–Mutated NSCLC

Can Deep Learning Models Predict Immunotherapy Response in Advanced NSCLC?

Researchers Look at Clinical Trial Eligibility Criteria for Those With Metastatic NSCLC

Surgery and Survival in Early-Stage Lung Cancer: Learning From Real-World Data

Combination of Chemotherapy, Immunotherapy, and Radiotherapy for NSCLC With Brain Metastases

EGFR-Mutant NSCLC: Weight Loss, Osimertinib, and Survival

Investigational Oral Therapy Receives Fast Track Designation for KRAS G12C–Mutated NSCLC

Study Plans to Evaluate Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

‘Knowing the Type of KRAS Mutation Is Critical’ in Managing KRAS-Mutant NSCLC

Use of Osimertinib and Cardiac Events: Is There a Connection?

Are Sodium Levels a Prognostic Indicator of Survival in Metastatic NSCLC?

Can Comprehensive Genome Profiling Determine the Right Treatment for Patients With NSCLC?

Can Selinexor Plus Docetaxel Improve Outcomes in Advanced KRAS-Mutant NSCLC?

FDA Approval: ALK Inhibitor Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC

Adding Radiotherapy to TKIs in Metastatic EGFR-Mutated NSCLC Population

Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC

Metformin: An Effective Treatment of Lung Cancer Among Patients With Obesity?

Algorithm for Capturing Disease Progression in Patients With Metastatic NSCLC

New Bispecific Antibody Granted Approval in NSCLC Harboring NRG1 Gene Fusion

Stage III NSCLC: Midtreatment PET-Adapted Radiotherapy Dose Escalation

California Researchers Awarded $2.5M Grant for Initiative to Reduce Disparities in Lung Cancer Screening

5-Year Outcomes From NADIM Trial Support Perioperative Chemoimmunotherapy in NSCLC

Creating Better Utility of Test Results in EGFR-Mutated Metastatic NSCLC

New Application for Accelerated Approval for Dato-DXd in Advanced EGFR-Mutated NSCLC

Chemoradiotherapy for Locally Advanced NSCLC: Is Dose Escalation the Answer to Local Tumor Control?

SITC 2024: Novel Method to Predict, Assess Immunotherapy Efficacy in NSCLC

SITC 2024: Updated Overall Survival From PERLA Trial in Metastatic Nonsquamous NSCLC

SITC 2024: Can Machine Learning Identify Treatment-Specific Outcomes and Biomarkers in NSCLC?

Wedge Resection or Lobectomy: Comparing Survival Benefits in NSCLC

SBRT vs Minimally Invasive Surgery in NSCLC: Clinical Model May Help in Selection Process

Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

Using Machine Learning Model to Predict NSCLC Progression After Upfront Pembrolizumab

Combination Regimen vs Docetaxel in Advanced NSCLC

10-Year Update on Proton vs Photon Radiotherapy for Locally Advanced NSCLC

Perioperative Use of Ivonescimab in Resectable NSCLC

FDA Approves Tumor Treating Fields Therapy for Metastatic NSCLC

Exploring Comprehensive Biomarker Testing in Patients With NSCLC

Insights on Concomitant Driver Alterations in EGFR-Mutated NSCLC

ASTRO 2024: Combination of High-Dose Radiotherapy and Immunotherapy for Metastatic NSCLC

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC